Wet Age Related Macular Degeneration Stocks List

Symbol	Grade	Name	% Change
ADVM	F	Adverum Biotechnologies, Inc.	5.04
EYPT	F	EyePoint Pharmaceuticals, Inc.	7.19
RGNX	F	REGENXBIO Inc.	4.47
OTLK	F	Outlook Therapeutics, Inc.	-1.95
CLSD	F	Clearside Biomedical, Inc.	5.88
KALA	C	Kala Pharmaceuticals, Inc.	3.74
KOD	C	Kodiak Sciences Inc	4.92
BNTC	C	Benitec Biopharma Limited	2.84
OMER	A	Omeros Corporation	41.14

Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic

Symbol	Grade	Name	Weight
QQQS	B	Invesco NASDAQ Future Gen 200 ETF	1.9
XPH	B	SPDR S&P Pharmaceuticals ETF	0.94
GNOM	F	Global X Genomics & Biotechnology ETF	0.87
WDNA	F	WisdomTree BioRevolution Fund	0.67
BBC	F	Virtus LifeSci Biotech Clinical Trials ETF	0.64

Compare ETFs

Date	Stock	Title
Nov 22	OMER	Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News
Nov 22	OMER	Omeros surges 22% on clarity for BLA resubmission for narsoplimab
Nov 21	OMER	Omeros Corporation Provides Update on Progress Toward BLA Resubmission
Nov 20	ADVM	Adverum Biotechnologies Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Nov 18	ADVM	Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients
Nov 18	RGNX	Regenxbio surges 10% as it launches pivotal phase of muscular dystrophy asset trial
Nov 18	ADVM	Adverum Reports Positive Ixo-vec Data for Wet Age-Related Macular Degeneration; Shares Rise Pre-Bell
Nov 18	RGNX	REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Nov 18	ADVM	Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
Nov 18	RGNX	FDA endorses speedy approval path for Regenxbio Duchenne gene therapy

Wet Age Related Macular Degeneration: Wet Age Related Macular Degeneration (AMD) is a condition that affects the macula, the part of the eye responsible for central vision. It is caused by abnormal blood vessels that grow underneath the macula and leak fluid or blood, causing damage to the macula and leading to vision loss. Wet AMD is the more severe form of AMD and can cause vision loss more quickly than the dry form. Treatment for wet AMD includes injections of medications into the eye, laser treatments, and photodynamic therapy.